MiNK Therapeutics, Inc. (INKT) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. SPY
9. IVBIY
10. FIX

Go back to MiNK Therapeutics, Inc. (INKT) Tops Q2 EPS by 5c

MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results

August 9, 2022 8:00 AM EDT

Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022Under the leadership team of Dr. Joy Zhou, completed internal cGMP production of AgenT-797 with expansion capacity to treat >700,000 patients/yearAgenT-797 for the treatment of infections and viral ARDS identified as selectable for funding by DARPA; contract negotiations underway

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MiNK... More